This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nutt, C. L. Articles by Hockfield, S. Search for Related Content PubMed PubMed Citation Articles by Nutt, C. L. Articles by Hockfield, S. Social Bookmarking                         What's this?

Glial Tumor Invasion: A Role for the Upregulation and Cleavage of BEHAB/Brevican

Molecular Neuro-Oncology Laboratory, Massachusetts General Hospital, Charles town, Massachusetts, nutt{at}helix.mgh.harvard.edu

Russell T. Matthews

Sec tion of Neurobiology, Yale University School of Medicine, New Haven, Connecticut

Susan Hockfield

Section of Neurobiology, Yale University School of Medicine, New Haven, Connecticut

Glial tumors, gliomas, are the most common primary intracranial tumors. Their distinct ability to invade the normal surrounding tissue makes them difficult to control and nearly impossible to completely remove surgically, and it accounts for the extraordinarily high lethality associated with gliomas. The ability of these transformed glial cells to invade the normal surrounding tissue is relatively unique in the adult CNS, which under most circumstances, is inhibitory to cell movement. The extracellular matrix (ECM) can modulate, in part, the permissiveness of a tissue to cell movement. Accordingly, the ability of gliomas to modify the ECM of the CNS may mediate the invasiveness of these cells. One ECM molecule that shows dramatic upregulation in gliomas is BEHAB (brain enriched hyaluronan binding)/brevican, a brain-specific chondroitin sulfate proteoglycan. BEHAB/brevican expression is also upregulated during periods of increased glial cell motility in development and following brain injury. Experimental evidence suggests that in glioma, in addition to upregulation of BEHAB/brevican, proteolytic processing of the full-length protein also may contribute to invasion. Here, the authors present a review of the literature on glial tumor invasion by modulation of the ECM and propose a two-step model for BEHAB/brevican’s role in this process.

Key Words: Glioma • Invasion • Extracellular matrix • BEHAB • Brevican • ADAMTS

The Neuroscientist, Vol. 7, No. 2, 113-122 (2001)
DOI: 10.1177/107385840100700206


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. Hu, L. L. Kong, R. T. Matthews, and M. S. Viapiano The Proteoglycan Brevican Binds to Fibronectin after Proteolytic Cleavage and Promotes Glioma Cell Motility J. Biol. Chem., September 5, 2008; 283(36): 24848 - 24859. [Abstract] [Full Text] [PDF]

				Y. Liang, M. Diehn, N. Watson, A. W. Bollen, K. D. Aldape, M. K. Nicholas, K. R. Lamborn, M. S. Berger, D. Botstein, P. O. Brown, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme PNAS, April 19, 2005; 102(16): 5814 - 5819. [Abstract] [Full Text] [PDF]

				M. S. Viapiano, R. T. Matthews, and S. Hockfield A Novel Membrane-associated Glycovariant of BEHAB/Brevican Is Up-regulated during Rat Brain Development and in a Rat Model of Invasive Glioma J. Biol. Chem., August 29, 2003; 278(35): 33239 - 33247. [Abstract] [Full Text] [PDF]

				H. M. Fathallah-Shaykh Darts in the Dark Cure Animal, but Not Human, Brain Tumors Arch Neurol, May 1, 2002; 59(5): 721 - 724. [Full Text] [PDF]

				C. L. Nutt, C. A. Zerillo, G. M. Kelly, and S. Hockfield Brain Enriched Hyaluronan Binding (BEHAB)/Brevican Increases Aggressiveness of CNS-1 Gliomas in Lewis Rats Cancer Res., October 1, 2001; 61(19): 7056 - 7059. [Abstract] [Full Text] [PDF]